15 citations
,
January 2019 in “Lasers in surgery and medicine” Home-use light devices can significantly reduce hair but are less effective on very dark skin and slower than professional devices.
January 2019 in “Archives of dermatology and skin care” Microneedling with oral collagen improves wrinkles better than microneedling alone.
260 citations
,
July 2010 in “Cell” Mutations in the SRD5A3 gene cause a new type of glycosylation disorder by blocking the production of a molecule necessary for protein glycosylation.
27 citations
,
December 2020 in “Experimental Dermatology” Grey hair and baldness may be linked to COVID-19 severity, but more analysis is needed; post-infectious hair loss is related to the severity of the disease and usually recovers within 3-6 months.
14 citations
,
January 2019 in “Skin appendage disorders” PFS might be a delusional disorder with potential to become mass psychogenic illness.
14 citations
,
June 2018 in “JAMA Dermatology” Trichoscopy is useful for diagnosing and monitoring hair and scalp conditions over time.
14 citations
,
January 2018 in “Skin Appendage Disorders” Upper eyelid hyperpigmentation can help diagnose facial lichen planus pigmentosus in patients with frontal fibrosing alopecia.
11 citations
,
January 2018 in “International Journal of Trichology” The true incidence of post-Finasteride syndrome is unclear, and more research is needed.
9 citations
,
January 2018 in “International Journal of Trichology” A woman's hair loss from graft versus host disease helps understand similar hair loss conditions.
7 citations
,
January 2018 in “International Journal of Trichology” Wearing a wig caused a skin condition to develop in a woman with hair loss.
4 citations
,
January 2021 in “Skin appendage disorders” Trichodynia is a painful scalp condition not directly linked to the amount or type of hair loss and may involve psychological factors, with treatments showing mixed results.
3 citations
,
March 2021 in “Journal of the European Academy of Dermatology and Venereology” The letter is skeptical about the effectiveness of anti-androgen therapy for COVID-19 and calls for strong evidence from clinical trials.
3 citations
,
November 2020 in “Journal of The American Academy of Dermatology” The document suggests that more research is needed to confirm if baldness can indicate a higher risk of severe COVID-19 in men.
3 citations
,
January 2019 in “International Journal of Trichology” The article concludes that treating hair loss requires careful research, understanding the causes, and personalized treatment plans.
2 citations
,
August 2021 in “Revista Da Associacao Medica Brasileira” The COVID-19 pandemic has increased hair loss and psychological distress in women.
1 citations
,
April 2022 in “Revista Da Associacao Medica Brasileira” COVID-19 can cause different types of hair loss, and proper diagnosis by a specialist may be needed.
1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
1 citations
,
January 2021 in “Skin appendage disorders”
1 citations
,
November 2020 in “Journal of The American Academy of Dermatology” The commentary suggests that certain hair and skin care products may be linked to frontal fibrosing alopecia, but not sunscreens, and calls for more thorough research on the causes.
1 citations
,
March 2018 in “bioRxiv (Cold Spring Harbor Laboratory)” The hair treatment made hair grow faster and thicker and strengthened the hair roots.
April 2026 in “Journal of Investigative Dermatology” Mechanotransduction aids healthy wound healing by promoting specific fibroblasts.
Virtual healthcare significantly improves quality of life for men with hair loss if they stick to the treatment.
The TrichoConcept™ line is effective for personalized hair loss treatments.
DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.
TrichoSol™ effectively stabilizes various hair treatment ingredients for different durations.
January 2025 in “Current Drug Delivery” TrichoSol™ and TrichoFoam™ are stable and effective for personalized alopecia treatments.
January 2025 in “Surgical & Cosmetic Dermatology” Histopathological confirmation is crucial to accurately diagnose alopecia triangular temporal and avoid unnecessary treatments.
December 2024 in “PubMed” TrichoFoam™ effectively delivers multiple hair loss treatments, maintaining their stability and effectiveness.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
September 2024 in “Journal of the American Academy of Dermatology” The compounded topical solution is safe, stable, and effective for personalized alopecia treatment.